HK1131971A1 - Benzimidazole modulators of vr1 vr1 - Google Patents

Benzimidazole modulators of vr1 vr1

Info

Publication number
HK1131971A1
HK1131971A1 HK09109915.4A HK09109915A HK1131971A1 HK 1131971 A1 HK1131971 A1 HK 1131971A1 HK 09109915 A HK09109915 A HK 09109915A HK 1131971 A1 HK1131971 A1 HK 1131971A1
Authority
HK
Hong Kong
Prior art keywords
benzimidazole
modulators
benzimidazole modulators
compounds
directed
Prior art date
Application number
HK09109915.4A
Other languages
English (en)
Inventor
Raul R Calvo
Mark R Player
Scott L Dax
William H Parsons
Michael Brandt
Sharmila Patel
Jian Liu
Wing S Cheung
Michele C Jetter
Yu-Kai Lee
Mark A Youngman
Wenxi Pan
Kenneth M Wells
Derek A Beauchamp
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1131971A1 publication Critical patent/HK1131971A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HK09109915.4A 2006-05-03 2009-10-27 Benzimidazole modulators of vr1 vr1 HK1131971A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79750406P 2006-05-03 2006-05-03
PCT/US2007/066748 WO2007130780A2 (en) 2006-05-03 2007-04-17 Benzimidazole modulators of vr1

Publications (1)

Publication Number Publication Date
HK1131971A1 true HK1131971A1 (en) 2010-02-12

Family

ID=38566108

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09109915.4A HK1131971A1 (en) 2006-05-03 2009-10-27 Benzimidazole modulators of vr1 vr1

Country Status (37)

Country Link
US (3) US7951829B2 (xx)
EP (1) EP2021330B1 (xx)
JP (1) JP5302884B2 (xx)
KR (1) KR101434883B1 (xx)
CN (1) CN101511797B (xx)
AR (1) AR060840A1 (xx)
AT (1) ATE482201T1 (xx)
AU (1) AU2007248341C1 (xx)
BR (1) BRPI0709803B8 (xx)
CA (1) CA2651128C (xx)
CO (1) CO6160329A2 (xx)
CR (1) CR10479A (xx)
CY (1) CY1111269T1 (xx)
DE (1) DE602007009378D1 (xx)
DK (1) DK2021330T3 (xx)
EA (1) EA019386B1 (xx)
EC (1) ECSP088854A (xx)
ES (1) ES2350959T3 (xx)
HK (1) HK1131971A1 (xx)
HR (1) HRP20100700T1 (xx)
IL (1) IL194916A (xx)
JO (1) JO3602B1 (xx)
MX (1) MX2008014108A (xx)
MY (1) MY154595A (xx)
NI (1) NI200800290A (xx)
NO (1) NO341965B1 (xx)
NZ (1) NZ572251A (xx)
PE (1) PE20080065A1 (xx)
PL (1) PL2021330T3 (xx)
PT (1) PT2021330E (xx)
RS (1) RS51473B (xx)
SI (1) SI2021330T1 (xx)
TW (1) TWI419882B (xx)
UA (1) UA94749C2 (xx)
UY (1) UY30322A1 (xx)
WO (1) WO2007130780A2 (xx)
ZA (1) ZA200810234B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101503286B1 (ko) * 2006-12-15 2015-03-17 얀센 파마슈티카 엔.브이. 벤즈이미다졸 trpv1 저해제
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
JP5562865B2 (ja) * 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Trpv1のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
US20090156598A1 (en) * 2007-12-17 2009-06-18 Lebsack Alec D Imidazolopyrimidine modulators of TRPV1
JP5372138B2 (ja) * 2008-04-18 2013-12-18 テウン ファーマシューティカル カンパニー,リミテッド 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
US8217060B2 (en) * 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US8323805B2 (en) * 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
CN102002010A (zh) * 2009-08-31 2011-04-06 住友化学株式会社 双噁唑啉基烷烃化合物的精制方法
JP5833745B2 (ja) 2011-05-16 2015-12-16 セルシューティクス・コーポレーション 粘膜炎の治療に使用するための化合物
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
WO2014143638A1 (en) 2013-03-14 2014-09-18 Novartis Ag 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
MX366875B (es) * 2013-07-11 2019-07-29 Bristol Myers Squibb Co Inhibidores de indoleamina 2,3-dioxigenasa (ido).
JP2016535042A (ja) 2013-10-30 2016-11-10 ノバルティス アーゲー 2−ベンジル−ベンゾイミダゾール補体因子b阻害剤およびその使用
CN108026071A (zh) * 2015-09-08 2018-05-11 住友化学株式会社 制备三唑化合物的方法
JP7041141B2 (ja) * 2016-11-01 2022-03-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
PL3781161T3 (pl) * 2018-05-03 2023-10-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pochodne benzimidazolu jako modulatory receptora sierocego gamma związanego z retinoidami (rory) oraz ich zastosowania farmaceutyczne
CN108997398B (zh) * 2018-07-23 2020-12-15 被忽略疾病药物研发组织 一种3,3-二甲基苯并[c][1,2]氧杂戊硼烷-1(3h)-醇的制备方法
KR20220093340A (ko) * 2019-10-31 2022-07-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 RORγ 조절제의 산부가염
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6299796B1 (en) 1997-12-18 2001-10-09 Fuji Photo Film Co., Ltd. Styryl compound, method for the preparation thereof and electroluminescent element employing the same
US6748803B1 (en) * 2000-02-22 2004-06-15 Simmonds Precison Products, Inc. Liquid measurement system and shared interface apparatus for use therein
JP2006505570A (ja) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
EP1660492B1 (en) * 2003-07-28 2008-08-20 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
US7309716B2 (en) * 2003-10-28 2007-12-18 Vertex Pharmaceuticals Incorporated Benzimidazoles useful as modulators of ion channels
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
ATE459352T1 (de) * 2006-07-04 2010-03-15 Janssen Pharmaceutica Nv Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
KR101503286B1 (ko) * 2006-12-15 2015-03-17 얀센 파마슈티카 엔.브이. 벤즈이미다졸 trpv1 저해제

Also Published As

Publication number Publication date
IL194916A (en) 2013-01-31
EP2021330A2 (en) 2009-02-11
MY154595A (en) 2015-06-30
BRPI0709803A2 (pt) 2011-07-26
NZ572251A (en) 2010-08-27
ATE482201T1 (de) 2010-10-15
CA2651128A1 (en) 2007-11-15
AU2007248341A1 (en) 2007-11-15
JP2009535414A (ja) 2009-10-01
CO6160329A2 (es) 2010-05-20
CA2651128C (en) 2014-09-02
PT2021330E (pt) 2010-12-03
WO2007130780A3 (en) 2008-02-14
US7951829B2 (en) 2011-05-31
IL194916A0 (en) 2009-08-03
HRP20100700T1 (hr) 2011-02-28
AU2007248341C1 (en) 2013-01-17
CR10479A (es) 2009-03-31
KR20090008428A (ko) 2009-01-21
BRPI0709803B1 (pt) 2019-12-10
EP2021330B1 (en) 2010-09-22
CN101511797A (zh) 2009-08-19
SI2021330T1 (sl) 2011-01-31
JP5302884B2 (ja) 2013-10-02
US20110190344A1 (en) 2011-08-04
TWI419882B (zh) 2013-12-21
CN101511797B (zh) 2013-01-02
UA94749C2 (xx) 2011-06-10
AU2007248341B2 (en) 2011-12-08
EA019386B1 (ru) 2014-03-31
TW200808738A (en) 2008-02-16
KR101434883B1 (ko) 2014-08-27
ZA200810234B (en) 2010-02-24
US20070259936A1 (en) 2007-11-08
DE602007009378D1 (de) 2010-11-04
NO341965B1 (no) 2018-03-05
PE20080065A1 (es) 2008-02-25
AR060840A1 (es) 2008-07-16
ES2350959T3 (es) 2011-01-28
WO2007130780A2 (en) 2007-11-15
MX2008014108A (es) 2008-11-14
PL2021330T3 (pl) 2011-03-31
US20110190364A1 (en) 2011-08-04
NO20085031L (no) 2009-01-06
JO3602B1 (ar) 2020-07-05
DK2021330T3 (da) 2010-12-06
ECSP088854A (es) 2008-11-27
RS51473B (en) 2011-04-30
BRPI0709803B8 (pt) 2021-05-25
EA200870497A1 (ru) 2009-06-30
NI200800290A (es) 2012-01-30
UY30322A1 (es) 2007-08-31
CY1111269T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
HK1131971A1 (en) Benzimidazole modulators of vr1 vr1
MX2009003080A (es) Compuestos organicos heterociclicos.
MX2009006473A (es) Inhibidores de receptor vainilloide de bencimidazol.
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
UA83311C2 (xx) 3-аміноциклопентанкарбоксаміди як модулятори хемокінових рецепторів$3-аминоциклопентанкарбоксамиды как модуляторы хемокиновых рецепторов
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
MX2009003227A (es) Moduladores de los receptores de glutamato metabotropicos 5(mglur5).
TW200716134A (en) Tricyclic opioid modulators
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
MEP1008A (xx) 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
HK1132742A1 (en) Substituted oxindole derivative and its use as a vasopressin receptor modulator
SG158091A1 (en) Imidazoazepinone compounds
TW200942534A (en) Organic compounds
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
DE602007007934D1 (en) Imidazoazephinonverbindungen
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
EP2073635A4 (en) MACROCYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
UA96295C2 (xx) Антивірусні фосфінатні сполуки[антивирусные фосфинатные соединения